ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 30 大学院医学系研究科・医学部
  2. 30D 学位論文
  3. 博士論文 本文
  4. 2014年度

Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single- center experience

http://hdl.handle.net/10076/14725
http://hdl.handle.net/10076/14725
75878340-5cda-49c0-a3b2-58b10e56a62a
名前 / ファイル ライセンス アクション
2014DM019.pdf 2014DM019.pdf (662.7 kB)
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2015-10-22
タイトル
タイトル Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single- center experience
言語 en
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_db06
資源タイプ doctoral thesis
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
著者 藤森, 将志

× 藤森, 将志

en Fujimori, Masashi

ja-Kana フジモリ, マサシ

ja 藤森, 将志

Search repository
抄録
内容記述タイプ Abstract
内容記述 Purpose To report 10-year outcomes of treating hepatocellular carcinomas (HCCs) by combination therapy of chemoembolization and radiofrequency (RF) ablation. Materials and Methods Combination therapy was administered in 277 patients with 382 treatment-naïve HCCs. Therapeutic effects, safety, survival rate, and prognostic factors were evaluated. Results Tumor enhancement disappeared after 466 RF sessions in all tumors, resulting in a complete response rate of 100% (277 of 277) based on modified Response Evaluation Criteria In Solid Tumors. Local tumor progression developed in 15 patients (5.4%; 15 of 277) during the mean follow-up of 44.9 months±29.1 (range, 6.0–134.4 mo). Overall and recurrence-free survival rates were 56.3% (95% confidence interval [CI], 52.5%–60.2%) and 22.5% (95% CI, 19.3%–25.6%) at 5 years and 23.5% (95% CI, 17.7%–29.2%) and 9.3% (95% CI, 6.3%–12.4%) at 10 years. The Child-Pugh class was the only significant prognostic factor detected in both the univariate (P<.001) and the multivariate analyses (hazard ratio, 3.8; 95% CI, 2.5–5.6; P<.001). The 5-year and 10-year overall survival rates were 66.4% (95% CI, 62.0%–70.8%) and 30.6% (95% CI, 23.3%–37.9%) in 210 Child-Pugh class A patients. In addition to the Child-Pugh class, the maximum tumor diameter (≤3 cm vs>3 cm) and the tumor number (single vs multiple) were significant independent factors affecting recurrence-free survival. No death was related to the combination therapy. The major complication rate was 3.2% (15 of 466). Conclusions RF ablation combined with chemoembolization is a safe and useful therapeutic option for treating HCCs. Prognostic factors detected in this study help to stratify patients who benefit from this combination therapy.
内容記述
内容記述タイプ Other
内容記述 本文 / Department of Radiology, Mie University School of Medicine
内容記述
内容記述タイプ Other
内容記述 12p
書誌情報
発行日 2015-01-01
DOI
識別子タイプ DOI
関連識別子 10.1016/j.jvir.2012.12.009
フォーマット
内容記述タイプ Other
内容記述 application/pdf
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
出版者
出版者 三重大学
出版者(ヨミ)
値 ミエダイガク
関係URI
関連名称 http://www.sciencedirect.com/science/article/pii/S1051044312012870
学位名
学位名 博士(医学)
学位授与機関
学位授与機関識別子Scheme kakenhi
学位授与機関識別子 14101
学位授与機関名 三重大学
学位授与年月日
学位授与年月日 2015-03-25
学位授与番号
学位授与番号 甲医学第1704号
ノート
資源タイプ(三重大)
値 Doctoral Dissertation / 博士論文
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-19 16:49:08.151839
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3